Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Exploring the therapeutic efficacy difference in claudin18.2-targeted cell therapy revealed by single-cell sequencing

7 Jan 2025

Abstract excerpt

Chimeric antigen receptor T cell (CAR T) therapy has been successfully used to treat hematological malignancies. Nonetheless, its application to solid tumors remains challenging. Our previous analysis of the ongoing clinical trial (NCT03874897) demonstrated promising results in patients with advanced CLDN18.2-positive gastric cancer who received CT041 CAR T treatment. Here, we collected peripheral blood and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Single-cell and spatial transcriptomics
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39925434
DOI: 10.1016/j.isci.2025.111768

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Exploring the therapeutic efficacy difference in claudin18.2-targeted cell therapy revealed by single-cell sequencingPMID 39925434Read ↗

Claudin-18 Splice Variant 2 Is a Pan-Cancer Target Suitable for Therapeutic Antibody DevelopmentSemantic proximity Read ↗

Car-γδ T Cells Targeting Claudin18.2 Show Superior Cytotoxicity Against Solid Tumor Compared to Traditional Car-αβ T CellsSemantic proximity Read ↗

Spatial expression of claudin 18.2 in matched primaries and metastases of tubo-ovarian carcinoma of all subtypesSemantic proximity Read ↗

Prognostic significance of Claudin18.2 expression in patients with gastric cancer: Insights from original research and meta-analysisSemantic proximity Read ↗

Decoding CLU (Clusterin): Conquering cancer treatment resistance and immunological barriersSemantic proximity Read ↗

A Claudin-Based Molecular Signature Identifies High-Risk, Chemoresistant Colorectal Cancer PatientsSemantic proximity Read ↗

Claudin-1, A Double-Edged Sword in CancerSemantic proximity Read ↗

SLP-76/LAT AND-gated CAR-T cells mediate highly specific and durable antitumor activity in pancreatic ductal adenocarcinoma with reduced gastric toxicitySemantic proximity Read ↗

Immunohistochemical expression of Claudin18.2 in borderline and malignant gynecologic tumors: Results from a pilot studySemantic proximity Read ↗

Identification of Claudin-6 as a Molecular Biomarker in Pan-Cancer Through Multiple Omics Integrative AnalysisSemantic proximity Read ↗

CLDN6 and CLDN10 are Associated with Immune Infiltration of Ovarian Cancer: A Study of Claudin FamilySemantic proximity Read ↗

Treatment Selection for Patients with HER2-Negative Metastatic Gastric Cancer Expressing Claudin 18.2 and PD-L1Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.